Jaguar Health (JAGX) Depreciation & Amortization (CF) (2016 - 2026)
Jaguar Health (JAGX) posted quarterly Depreciation & Amortization (CF) of $473000.0 for Q1 2026, down 1.25% year-over-year from $479000.0 in Q1 2025, and down 0.84% quarter-over-quarter from $477000.0 in Q4 2025.
Jaguar Health (JAGX) Depreciation & Amortization (CF) (2016 - 2026) Analysis & Trends
Jaguar Health (JAGX) has reported Depreciation & Amortization (CF) for 11 consecutive years, with $473000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Depreciation & Amortization (CF) fell 1.25% year-over-year to $473000.0; the TTM figure through Mar 2026 stood at $1.9 million (up 1.54% YoY), while the FY2025 annual figure was $1.9 million, up 0.68% from the prior year.
- Depreciation & Amortization (CF) retreated to $473000.0 in Q1 2026 per JAGX's latest filing, from $477000.0 in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $558000.0 in Q2 2022 and bottomed at $426000.0 in Q1 2022.
- Historically, Depreciation & Amortization (CF) has averaged $487058.8 across 5 years, with a median of $479000.0 in 2025.
- Annual changes were most pronounced in 2022 — Depreciation & Amortization (CF) gained 29.77% — and 2024, when it declined 11.13%.
- Jaguar Health's Depreciation & Amortization (CF) stood at $499000.0 in 2022, then climbed by 0.6% to $502000.0 in 2023, then decreased by 4.78% to $478000.0 in 2024, then fell by 0.21% to $477000.0 in 2025, then declined by 0.84% to $473000.0 in 2026.
- Business Quant data shows JAGX's Depreciation & Amortization (CF) at $473000.0 in Q1 2026, $477000.0 in Q4 2025, and $479000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 40.52 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 191.83 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Jaguar Health | 447,549.24 | -9.62 Mn | 19.11 Mn | 473,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 473,000.00 |
| Mar 31, 2026 | 473,000.00 |
| Dec 31, 2025 | 477,000.00 |
| Dec 31, 2025 | 477,000.00 |
| Sep 30, 2025 | 479,000.00 |
| Sep 30, 2025 | 479,000.00 |
| Jun 30, 2025 | 478,000.00 |
| Jun 30, 2025 | 478,000.00 |
| Mar 31, 2025 | 479,000.00 |
| Mar 31, 2025 | 479,000.00 |
| Dec 31, 2024 | 478,000.00 |
| Dec 31, 2024 | 478,000.00 |
| Sep 30, 2024 | 474,000.00 |
| Sep 30, 2024 | 474,000.00 |
| Jun 30, 2024 | 447,000.00 |
| Jun 30, 2024 | 447,000.00 |
| Mar 31, 2024 | 501,000.00 |
| Mar 31, 2024 | 501,000.00 |
| Dec 31, 2023 | 502,000.00 |
| Dec 31, 2023 | 502,000.00 |